Okuda M, Senba O
Clin Otolaryngol Allied Sci. 1980 Oct;5(5):315-21. doi: 10.1111/j.1365-2273.1980.tb00897.x.
It was the aim of this trial to study the effect of intranasal beclomethasone dipropionate on symptoms and signs of perennial allergic rhinitis in Japanese patients. In a multicenter trial 183 patients, children and adults, were treated with placebo or with 400 microgram beclomethasone dipropionate a day for 2 weeks. The active treatment had an effect on all nasal symptoms: sneezing, nose blowing, and blockage being reduced to 34%, 44% and 63% (P < 0.01) of the values in the placebo group. A considerable carry-over effect was found, suggesting a group comparative design to be preferable for a cross over trial for the study of intranasal steroids. The beclomethasone dipropionate therapy had a significant inhibitory effect on the immediate response to nasal allergen provocation. The number of secretion eosinophils was reduced during treatment, and the appearance of the mucous membrane tended to normalize. Local side effects were few and insignificant. It is concluded that beclomethasone dipropionate is a valuable drug for the treatment of perennial allergic rhinitis.
本试验旨在研究丙酸倍氯米松鼻喷雾剂对日本常年性变应性鼻炎患者症状和体征的影响。在一项多中心试验中，183例儿童和成人患者接受了安慰剂治疗或每天400微克丙酸倍氯米松治疗，为期2周。积极治疗对所有鼻部症状均有效果：打喷嚏、擤鼻和鼻塞分别降至安慰剂组数值的34%、44%和63%（P < 0.01）。发现有相当大的残留效应，这表明对于鼻内用类固醇药物的交叉试验，组间比较设计更为可取。丙酸倍氯米松治疗对鼻过敏原激发的即刻反应有显著抑制作用。治疗期间分泌性嗜酸性粒细胞数量减少，黏膜外观趋于正常。局部副作用很少且不明显。结论是丙酸倍氯米松是治疗常年性变应性鼻炎的一种有价值的药物。
